Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tarryn Collings

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Current HIV/AIDS Reports|April 17, 2026
Expanding PrEP Access Through Decentralized Delivery ModelsAngela Tembo, Tarryn Collings, Tsitsi Nyamuzihwa, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 2, 2025
A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampicin-Resistant Pulmonary TuberculosisVeronique de Jager, Laurynas Mockeliunas, Huifang You, et al.
The Lancet. Infectious Diseases|March 8, 2025
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trialÁlvaro H Borges, Marisa Russell, Dereck Tait, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Current HIV/AIDS Reports|April 17, 2026
Expanding PrEP Access Through Decentralized Delivery ModelsAngela Tembo, Tarryn Collings, Tsitsi Nyamuzihwa, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 2, 2025
A Phase 2a Study of the Early Bactericidal Activity of Rifampicin in Combination With Meropenem Plus Amoxicillin/Clavulanate Among Adults With Rifampicin-Resistant Pulmonary TuberculosisVeronique de Jager, Laurynas Mockeliunas, Huifang You, et al.
The Lancet. Infectious Diseases|March 8, 2025
Immunogenicity, safety, and efficacy of the vaccine H56:IC31 in reducing the rate of tuberculosis disease recurrence in HIV-negative adults successfully treated for drug-susceptible pulmonary tuberculosis: a double-blind, randomised, placebo-controlled, phase 2b trialÁlvaro H Borges, Marisa Russell, Dereck Tait, et al.
Pageof 1